How Long Does Paxlovid Take to Work: What to Expect

Paxlovid begins fighting the virus within hours of your first dose, but most people notice meaningful symptom improvement within two to three days of starting treatment. The drug works by blocking the virus from replicating, so it doesn’t eliminate symptoms instantly the way a painkiller might. Instead, it starves the infection of new copies of itself, giving your immune system the upper hand to clear things up faster.

How Paxlovid Works Inside Your Body

SARS-CoV-2 relies on a specific enzyme to chop its proteins into functional pieces and assemble new copies of itself. Paxlovid’s active ingredient jams that enzyme, effectively stopping the virus from multiplying. The second ingredient in the pill slows your liver from breaking down the first one, keeping drug levels high enough in your bloodstream to maintain constant pressure on the virus.

This mechanism means the drug doesn’t kill virus particles that already exist. It prevents new ones from being made. Your immune system still has to mop up what’s already there, which is why symptoms don’t vanish overnight. Think of it like turning off a faucet while the sink is still full: the water level drops, but not all at once.

What the First Few Days Look Like

The treatment course is five days, with pills taken twice daily. Here’s the general timeline most people experience:

  • Day 1: The drug reaches effective levels in your blood quickly, but you’re unlikely to feel different yet. Viral replication is being suppressed behind the scenes.
  • Days 2 to 3: Many people notice their fever breaking and fatigue starting to lift. Congestion, sore throat, and body aches typically begin easing. This is when the drop in viral load becomes large enough for your body to feel the difference.
  • Days 4 to 5: Symptoms continue improving. Some people feel nearly back to normal by the end of the course, while others still have lingering mild symptoms like a cough or fatigue.

Individual results vary depending on how early you started treatment, your vaccination status, your age, and your overall health. But the pattern of noticeable improvement in the first two to three days is consistent across most reports.

Why Timing Matters So Much

Paxlovid must be started within five days of your first symptoms. But “within five days” is the outer limit, not the sweet spot. Research published in eLife found that starting Paxlovid three to five days after symptoms begin may actually maximize the drug’s ability to reduce viral load and minimize the chance of rebound. Interestingly, patients treated fewer than three days after symptoms started were more likely to experience rebounding viral growth after finishing the course, and the early treatment didn’t reduce how infectious they were to others as effectively.

That finding might seem counterintuitive. The reason is that if you suppress the virus before your immune system has had a chance to ramp up its response, the virus can bounce back once you stop taking the pills. Starting at three to five days gives your immune system enough time to begin mounting a defense while the drug keeps viral replication in check.

Once you’ve been sick for more than a week, the drug loses much of its value. At that point, any serious damage being done to the body is driven by your own inflammatory response rather than by active viral replication, and an antiviral can’t undo that.

How Much It Reduces Serious Illness

In early clinical trials involving unvaccinated, high-risk patients, Paxlovid reduced the risk of hospitalization and death by 89% when started within three days of symptoms. That number came from a period before widespread vaccination and prior infection.

Real-world data from 2022, tracked by the CDC across nearly 700,000 U.S. adults (including vaccinated people and those with prior infections), showed a 51% lower hospitalization rate among those prescribed Paxlovid within five days of diagnosis compared to those who weren’t. That protection held across age groups: a 59% reduction for adults 18 to 49, 60% for those 50 to 64, and 53% for those 65 and older. Among people who had received three or more vaccine doses, Paxlovid still cut hospitalization risk in half. Death rates were also lower: 0.01% among those who took Paxlovid versus 0.04% among those who didn’t.

Paxlovid Rebound

Some people feel better, test negative, and then experience a return of symptoms or a positive test. This is commonly called “Paxlovid rebound,” and it typically happens between two and eight days after initial recovery. Symptoms during rebound are generally mild, and most people recover again without additional treatment.

Rebound doesn’t mean the drug failed. It means viral replication resumed after the five-day course ended, likely because the immune system hadn’t fully cleared the infection yet. This is more common when treatment is started very early in the illness (before day three of symptoms), which lines up with the timing research mentioned above. Rebound is not dangerous for most people, but you are potentially contagious again during that window.

Practical Tips While Taking It

You’ll take three pills together, twice a day, for five days. The pills can be taken with or without food. If you miss a dose and it’s been fewer than eight hours since you were supposed to take it, go ahead and take it. If more than eight hours have passed, skip that dose and pick back up at the next scheduled time. Never double up.

One of the most common complaints is a metallic or bitter taste in the mouth, sometimes called “Paxlovid mouth.” It’s harmless and goes away after you finish the course. Some people find that sucking on hard candy or chewing gum helps.

Paxlovid interacts with a long list of medications because the ritonavir component affects how your liver processes drugs. If you take blood thinners, certain heart medications, cholesterol-lowering statins, or immunosuppressants, your prescriber will need to review your medication list carefully. People with moderate kidney impairment take a reduced dose. Those with severe kidney or liver disease may not be candidates for the drug at all.